Optic pathway gliomas

Journal of Neuro-Ophthalmology

Volumn 31, Issue 3, 2011, Pages 269-278

  Avery, Robert A ^a   Fisher, Michael J ^b,c   Liu, Grant T ^b,c  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; ETOPOSIDE; LOMUSTINE; NEUROFIBROMIN; PROCARBAZINE; TEMOZOLOMIDE; TIOGUANINE; VINBLASTINE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHILDHOOD CANCER; CLINICAL FEATURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; GLIOMA; HUMAN; NEUROFIBROMATOSIS; NEUROIMAGING; OPTIC NERVE TUMOR; OPTIC PATHWAY GLIOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR GROWTH;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHILD, PRESCHOOL; FEMALE; GLIOMA; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEURAL PATHWAYS; OPTIC NERVE NEOPLASMS;

EID: 80052209726     PISSN: 10708022     EISSN: 15365166     Source Type: Journal    
DOI: 10.1097/WNO.0b013e31822aef82     Document Type: Review

References (92)

1. Lynch TM, Gutmann DH. Neurofibromatosis 1. Neurol Clin. 2002;20:841-865. (Pubitemid 35154470)
2. Fisher MJ, Balcer L, Gutmann D, Listernick R, Ferner R, Packer R, Hoffman R, Tabori U, Ullrich N, Ardern-Holmes S, Hargrave D, Bouffet E, Loguidice M, Liu GT. Neurofibromatosis type 1 associated optic glioma visual outcomes following chemotherapy: An international multi-center retrospective analysis [abstract]. Neuro Oncology. 2010;12:ii19.
3. Listernick R, Ferner FE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: Controversies and recommendations. Ann Neurol. 2007;61:189-198. (Pubitemid 46557343)
4. Miller NR. Optic pathway gliomas are tumors. Ophthal Plast Reconstr Surg. 2008;24:433.
5. Kornreich L, Blaser S, Schwarz M, Shuper A, Vishne TH, Cohen IJ, Faingold R, Michovitz S, Koplewitz B, Horev G. Optic pathway glioma: Correlation of imaging findings with the presence of neurofibromatosis. ANJR Am J Neuroradiol. 2001;22:1963-1969. (Pubitemid 33091970)
6. Nicolin G, Parkin P, Mabbott D, Hargrave D, Bartels U, Tabori U, Rutka J, Buncic JR, Bouffet E. Natural history and outcome of optic pathway gliomas in children. Pediatr Blood Cancer. 2009;53:1231-1237.
7. Listernick R, Charrow J, Greenwald M, Mets M. Natural history of optic pathway tumors in children with neurofibromatosis type 1: A longitudinal study. J Pediatr. 1994;125:63-66. (Pubitemid 24225179)
8. Blazo MA, Lewis RA, Chintagumpala MM, Frazier M, McCluggage C, Plon SE. Outcomes of systematic screening for optic pathway tumors in children with neurofibromatosis type 1. Am J Med Genet. 2004;127:224-229. (Pubitemid 38685860)
9. Thiagalingam S, Flaherty M, Billson F, North K. Neurofibromatosis type 1 and optic pathway gliomas: Followup of 54 patients. Ophthalmology. 2004;111:568-577. (Pubitemid 38293118)
10. Listernick R, Ferner RE, Piersall L, Sharif S, Gutmann DH, Charrow J. Late-onset optic pathway tumors in children with neurofibromatosis 1. Neurology. 2004;63:1944-1946. (Pubitemid 39532398)
11. Singhal S, Birch JM, Kerr B, Lashford L, Evans DG. Neurofibromatosis type 1 and sporadic optic gliomas. Arch Dis Child. 2002;87:65-70. (Pubitemid 34753778)
12. Cummings TJ, Provenzale JM, Hunter SB, Friedman AH, Klintworth GK, Bigner SH, McLendon RE. Gliomas of the optic nerve: Histological, immunohistochemical (MIB-1 and p53), and MRI analysis. Acta Neuropathol. 2000;99: 563-570. (Pubitemid 30201320)
13. Ellis JA, Waziri A, Balmaceda C, Canoll P, Bruce JN, Sisti MB. Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients. J. Neurooncol. 2009;95:377-382.
14. Pasol J, Sternau L, Luetmer P, Giannini C. Rapid progressive unilateral visual loss in an elderly man. J Neuroophthalmol. 2010;30:188-192.
15. Koenig SB, Naidich TP, Zaparackas Z. Optic glioma masquerading as spasmus nutans. J Pediatr Ophthalmol Strabismus. 1982;19:20-24. (Pubitemid 12169126)
16. Lavery MA, O'Neill JF, Chu FC, Martyn LJ. Acquired nystagmus in early childhood: A presenting sign of intracranial tumor. Ophthalmology. 1984;91:425-453.
17. Chateil JF, Soussotte C, Pédespan JM, Brun M, Le Manh C, Diard F. MRI and clinical differences between optic pathway tumours in children with and without neurofibromatosis. Br J Radiol. 2001;74:24-31. (Pubitemid 32156627)
18. Balcer LJ, Liu GT, Heller G, Bilaniuk L, Volpe NJ, Galetta SL, Molloy PT, Phillips PC, Janss AJ, Vaughn S, Maguire MG. Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: Relation to tumor location by magnetic resonance imaging. Am J Ophthalmol. 2001;131:442-445. (Pubitemid 32273429)
19. Dobson V, Quinn GE, Siatkowski RM, Baker JD, Hardy RJ, Reynold JD, Trese MT, Tung B. Agreement between grating acuity at 1 year and Snellen acuity at age 5.5 years in the pretermchild. Invest Ophthalmol Vis Sci. 1999;40:496-503. (Pubitemid 29063848)
20. Moke PS, Turpin AH, Beck RW, Holmes JM, Repka MX, Birch EE, Hertle RW, Kraker RT, Miller JM, Johnson CA. Computerized method for visual acuity testing: Adaptation of the amblyopia treatment study visual acuity testing protocol. Am J Ophthalmol. 2001;132:903-909. (Pubitemid 33122171)
21. Chen SI, Chandna A, Norcia AM, Pettet M, Stone D. The repeatability of best corrected acuity in normal and amblyopic children 4 to 12 years of age. Invest Ophthalmol Vis Sci. 2006;47:614-619. (Pubitemid 46768388)
22. Kelly JP, Weiss AH. Comparison of pattern visual-evoked potentials to perimetry in the detection of visual loss in children with optic pathway gliomas. J AAPOS. 2006;10: 298-306. (Pubitemid 44279459)
23. Chang BC, Mirabella G, Yagev R, Banh M, Mezer E, Parkin PC, Westall CA, Buncic JR. Screening and diagnosis of optic pathway gliomas in children with neurofibromatosis type 1 by using sweep visual evoked potentials. Invest Ophthalmol Vis Sci. 2007;48:2895-2902. (Pubitemid 351261247)
24. Trisciuzzi MT, Riccardi R, Piccardi M, Iarossi G, Buzzonetti L, Dickmann A, Colosimo C Jr, Ruggiero A, Di Rocco C, Falsini B. A fast visual evoked potential method for functional assessment and follow-up of optic pathway gliomas. Clin Neurophysiol. 2004;115:217-226. (Pubitemid 38045617)
25. Wolsey DH, Larson SA, Creel D, Hoffman R. Can screening for optic nerve gliomas in patients with neurofibromatosis type 1 be performed with visual-evoked potential testing? J AAPOS. 2006;10:307-311. (Pubitemid 44279460)
26. Siatkowski RM. VEP testing and visual pathway gliomas: Not quite ready for prime time. J AAPOS. 2006;10: 293-295. (Pubitemid 44279475)
27. Avery RA, Liu GT, Fisher MJ, Quinn GE, Belasco JB, Phillips PC, Maguire MG, Balcer LJ. Retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol. 2011;151:542-549.
28. Chang L, El-Dairi MA, Frempong TA, Burner EL, Bhatti MT, Young TL, Leigh F. Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas. J AAPOS. 2010;14:511-517.
29. Phillips PH. Is optical coherence tomography indicated for the evaluation of patients with neurofibromatosis type 1? J AAPOS. 2010;14:467-468.
30. Brodsky MC. The ''pseudo-CSF'' signal of orbital optic glioma on magnetic resonance imaging: A signature of neurofibromatosis. Surv Ophthalmol. 1993;38:213-218. (Pubitemid 23297234)
31. Astrup J. Natural history and clinical management of optic pathway glioma. Br J Neurosurg. 2003;17:327-335. (Pubitemid 37243963)
32. Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010;9:906-920.
33. Yamamoto A, Miki Y, Urayama S, Fushimi Y, Okada T, Hanakawa T, Fukuyama H, Togashi K. Diffusion tensor fiber tractography of the optic radiation: Analysis with 6-, 12-, 40-, and 81-directional motion-probing gradients, a preliminary study. Am J Neuroradiol. 2007;28:92-96. (Pubitemid 46147542)
34. Hegedus B, Hughes FW, Garbow JR, Gianino S, Banerjee D, Kim K, Ellisman MH, Brantley MA Jr, Gutmann DH. Optic nerve dysfunction in a mouse model of neurofibromatosis-1 optic glioma. J Neuropathol Exp Neurol. 2009;68:542-551.
35. Nickerson JP, Salmela MB, Koski CJ, Andrews T, Filippi CG. Diffusion tensor imaging of the pediatric optic nerve: Intrinsic and extrinsic pathology compared to normal controls. J Magn Reson Imaging. 2010;32:76-81.
36. Fisher MJ. The use of positron emission tomography in the evaluation of tumors in children with neurofibromatosis type 1. PET Clin. 2008;3:531-549.
37. Molloy PT, Defeo R, Hunter J, Sadek A, Alavi A, Cnaan A, Phillips PC. Excellent correlation of FDG-PET imaging with clinical outcome in patients with neurofibromatosis type I and low grade astrocytomas. J Nucl Med. 1999;40:129P.
38. Moharir M, London K, Howman-Giles R, North K. Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1. Eur J Nucl Med Mol Imaging. 2010;37:1309-1317.
39. Parsa CF, Givrad S. Juvenile pilocytic astrocytomas do not undergo spontaneous malignant transformation: Designation as hamartomas. Br J Ophthal. 2008;92:40-46.
40. Hoffman HJ, Soloniuk DS, Humphreys RP, Drake JM, Becker LE, De Lima BO, Piatt JH Jr. Management and outcome of low-grade astrocytomas of the midline in children: A retrospective review. Neurosurgery. 1993;33: 964-971. (Pubitemid 23358389)
41. Laithier V, Grill J, Le Deley MC, Ruchoux MM, Couanet D, Doz F, Pichon F, Rubie H, Frappaz D, Vannier JP, Babin-Boilletot A, Sariban E, Chastagner P, Zerah M, Raquin MA, Hartmann O, Kalifa C; French Society of Pediatric Oncology. Progression-free survival in children with optic pathway tumors: Dependence on age and the quality of the response to chemotherapy-results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol. 2003;21:4572-4578. (Pubitemid 46594029)
42. Sutton LN, Molloy PT, Sernyak H, Goldwein J, Phillips PL, Rorke LB, Moshang T Jr, Lange B, Packer RJ. Long-term outcome of hypothalamic/chiasmatic astrocytomas in children treated with conservative surgery. J Neurosurg. 1995;83:583-589.
43. Giannini C, Scheithauer BW, Burger PC, Christensen MR, Wollan PC, Sebo TJ, Forsyth PA, Hayostek CJ. Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol. 1999;58:46-53. (Pubitemid 29053025)
44. Haapasalo H, Sallinen S, Sallinen P, Helén P, Jää skeläinen J, Salmi TT, Paetau A, Paljärvi L, Visakorpi T, Kalimo H. Clinicopathological correlation of cell proliferation, apoptosis and p53 in cerebellar pilocytic astrocytomas. Neuropathol Appl Neurobiol. 1999;25:134-142. (Pubitemid 29221763)
45. Bowers DC, Gargan L, Kapur P, Reisch JS, Mulne AF, Shapiro KN, Elterman RD, Winick NJ, Margraf LR. Study of the MIB-1 labeling index as a predictor of tumor progression in pilocytic astrocytomas in children and adolescents. J Clin Oncol. 2003;21:2968-2973. (Pubitemid 46621849)
46. Cummings TJ, Provenzale JM, Hunter SB, Friedman AH, Klintworth GK, Bigner SH, McLendon RE. Gliomas of the optic nerve: Histological, immunohistochemical (MIB-1 and p53), and MRI analysis. Acta Neuropathol. 2000;99:563-570. (Pubitemid 30201320)
47. Parsa CF, Hoyt CS, Lesser RL, Weinstein JM, Strother CM, Muci-Mendoza R, Ramella M, Manor RS, Fletcher WA, Replea MX, Garrity JA, Ebner RN, Monteiro ML, McFadzean RM, Rubtsova IV, Hoyt WF. Spontaneous regression of optic gliomas: Thirteen cases documented by serial imaging. Arch Ophthalmol. 2001;119:516-529. (Pubitemid 32290060)
48. DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC, Lowy DR. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell. 1992;69: 265-273.
49. Gutmann DH. Using Neurofibromatosis-1 to better understand and treat pediatric low-grade glioma. J Child Neurol. 2008;23:1186-1194.
50. Hegedus B, Banerjee D, Yeh TH, Rothermich S, Perry A, Rubin JB, Garbow JR, Gutmann DH. Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res. 2008;68:1520-1528. (Pubitemid 351346861)
51. Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, Toedt G, Wittmann A, Kratz C, Olbrich H, Ahmadi R, Thieme B, Joos S, Radlwimmer B, Kulozik A, Pietsch T, Herold-Mende C, Gnekow A, Reifenberger G, Korshunov A, Scheurlen W, Omran H, Lichter P. BRAF gene duplication constitutes a mechanism ofMAPK pathway activation in lowgrade astrocytomas. J Clin Invest. 2008;118:1739-1749. (Pubitemid 351632377)
52. Bar EE, Lin A, Tihan T, Burger PC, Eberhart CG. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol. 2008;67:878-887.
53. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature. 2002;417: 949-954. (Pubitemid 34716871)
54. Yu J, Deshmukh H, Gutmann RJ, Emnett RJ, Rodriguez FJ, Watson MA, Nagarajan R, Gutmann DH. Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology. 2009;73:1526-1531.
55. Liu GT. Optic pathway gliomas. Curr Opin Ophthalmol. 2006;17:427-431.
56. Walrath JD, Engelbert M, Kazim M. Magnetic resonance imaging evidence of optic nerve glioma progression into and beyond the optic chiasm. Ophthal Plast Reconstr Surg. 2008;24:473-474.
57. Liu GT, Brodsky MC, Phillips PC, Belasco J, Janss A, Golden JC, Bilaniuk LL, Burson GT, Duhaime AC, Sutton LN. Optic radiation involvement in optic pathway gliomas in neurofibromatosis. Am J Ophthalmol. 2004;137:407-414. (Pubitemid 38328629)
58. Stokland T, Liu JF, Ironside JW, Ellison DW, Taylor R, Robinson KJ, Picton SV, Walker DA. A multivariate analysis of factors determining tumor progression in childhood lowgrade glioma: A population-based cohort study (CCLG CNS9702). Neuro Oncol. 2010;12:1257-1268.
59. Wisoff JH, Abbott R, Epstein F. Surgical management of exophytic chiasmatic-hypothalamic tumors of childhood. J Neurosurg. 1990;73:661-667. (Pubitemid 20364479)
60. Opocher E, Kremer LC, Da Dalt L, van de Wetering MD, Viscardi E, Caron HN, Perilongo G. Prognostic factors for progression of childhood optic pathway glioma: A systematic review. Eur J Cancer. 2006;42:1807-1816. (Pubitemid 44149098)
61. Nishio S, Takeshita I, Fujiwara S, Fukui M. Opticohypothalamic glioma: An analysis of 16 cases. Childs Nerv Syst. 1993;9:334-338.
62. Liu GT, Lessell S. Spontaneous visual improvement in chiasmal gliomas. Am J Ophthalmol. 1992;114:193-201.
63. Perilongo G, Moras P, Carollo C, Battistella A, Clementi M, Laverda A, Murgia A. Spontaneous partial regression of lowgrade glioma in children with neurofibromatosis-1: A real possibility. J Child Neurol. 1999;14:352-356. (Pubitemid 29321093)
64. Piccirilli M, Lenzi J, Delfinis C, Trasimeni G, SalvatiM, Raco A. Spontaneous regression of optic pathways gliomas in three patients with neurofibromatosis type I and critical review of the literature. Childs Nerv Syst. 2006;22:1332-1337. (Pubitemid 44446050)
65. Zuccoli G, Ferrozzi F, SigoriniM, Virdis R, Bassi P, BellomiM. Early spontaneous regression of a hypothalamic/chiasmatic mass in neurofibromatosis type 1: MR findings. Eur Radiol. 2000;10:1076-1078. (Pubitemid 30450815)
66. Bruggers CS, Friedman HS, Phillips PC, Wiener WD, Hockenberger B, Oakes WJ, Buckley EG. Leptomeningeal dissemination of optic pathway gliomas in three children. Am J Ophthalmol. 1991;111:719-723.
67. Perilongo G,CarollaC, Salviati L,MurgiaA, PillonM, BassoG, Gardiman M, Laverda A. Diencephalic syndrome and disseminated juvenile pilocytic astrocytomas of the hypothalamic-optic chiasm region. Cancer. 1997;80: 142-146. (Pubitemid 27270931)
68. Moreno L, Bautista F, Ashley S, Duncan C, Zacharoulis S. Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence. Eur J Cancer. 2010;46:2253-2259.
69. Fletcher WA, Imes RK, Hoyt WF. Chiasmal gliomas: Appearance and long-term changes demonstrated by computerized tomography. J Neurosurg. 1986;65: 154-159. (Pubitemid 16057484)
70. Sievert AJ, Fisher MJ. Pediatric low-grade gliomas. J Child Neurol. 2009;24:1397-1408.
71. Horwich A, Bloom HJ. Optic gliomas: Radiation therapy and prognosis. Int J Radiat Oncol Biol Phys. 1985;11: 1067-1079. (Pubitemid 15009562)
72. Bataini JP, Delanian S, Ponvert D. Chiasmal gliomas: Results of irradiation management in 57 patients and review of literature. Int J Radiat Oncol Biol Phys. 1991;21: 615-623.
73. Jenkin D, Angyalfi S, Becker L, Berry M, Buncic R, Chan H, Doherty M, Drake J, Greenberg M, Hendrick B. Optic glioma in children: Surveillance, resection, or irradiation? Int J Radiat Oncol Biol Phys. 1993;25:215-225.
74. Cappelli C, Grill J, Raquin M, Pierre-Kahn A, Lellouch-Tubiana A, Terrier-Lacombe MJ, Habrand JL, Couanet D, Brauner R, Rodriguez D, Hartmann O, Kalifa C. Long-term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era. Arch Dis Child. 1998;79: 334-338. (Pubitemid 28436086)
75. Grabenbauer GG, Schuchardt U, Buchfelder M, Rödel CM, Gusek G,Marx M, Doerr HG, Fahlbusch R, Huk WJ, Wenzel D, Sauer R. Radiation therapy of optico-hypothalamic gliomas (OHG)-radiographic response, vision and late toxicity. Radiother Oncol. 2000;54:239-245. (Pubitemid 30157834)
76. Pierce SM, Barnes PD, Loeffler JS, McGinn C, Tarbell NJ. Definitive radiation therapy in the management of symptomatic patients with optic glioma. Survival and longterm effects. Cancer. 1990;65:45-52. (Pubitemid 20026808)
77. Grill J, Couanet D, Cappelli C, Habrand JL, Rodriguez D, Sainte-Rose C, Kalifa C. Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann Neurol. 1999;45:393-396. (Pubitemid 29120046)
78. Kestle JR, Hoffman HJ, Mock AR. Moyamoya phenomenon after radiation for optic glioma. J Neurosurg. 1993;79: 32-35. (Pubitemid 23182740)
79. Lacaze E, Kieffer V, Streri A, Lorenzi C, Gentaz E, Habrand JL, Dellatolas G, Kalifa C, Grill J. Neuropsychological outcome in children with optic pathway tumours when first-line treatment is chemotherapy. Br J Cancer. 2003;89:2038-2044. (Pubitemid 38030900)
80. Sharif S, Ferner R, Birch JM, Gillespie JE, Gattamaneni HR, Baser ME, Evans DG. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: Substantial risks after radiotherapy. J Clin Oncol. 2006;24: 2570-2575. (Pubitemid 46630636)
81. Ullrich NJ, Robertson R, Kinnamon DD, Scott RM, KieranMW, Turner CD, Chi SN, Goumnerova L, Proctor M, Tarbell NJ, Marcus KJ, Pomeroy SL. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology. 2007;68:932-938. (Pubitemid 46568506)
82. Saran FH, Baumert BG, Khoo VS, Adams EJ, Garré ML, Warrington AP, Brada M. Stereotactically guided conformal radiotherapy for progressive low-grade gliomas of childhood. Int J Radiat Oncol Biol Phys. 2002;53:43-51. (Pubitemid 34465806)
83. Combs SE, Schulz-Ertner D, Moschos D, Thilmann C, Huber PE, Debus J. Fractionated stereotactic radiotherapy of optic pathway gliomas: Tolerance and long-term outcome. Int J Radiat Oncol Biol Phys. 2005;62:814-819. (Pubitemid 40779774)
84. Marcus KJ, Goumnerova L, Billett AL, Lavally B, Scott RM, Bishop K, Xu R, Young Poussaint T, Kieran M, Kooy H, Pomeroy SL, Tarbell NJ. Stereotactic radiotherapy for localized low-grade gliomas in children: Final results of a prospective trial. Int J Radiat Oncol Biol Phys. 2005;61: 374-379. (Pubitemid 40164429)
85. Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS, Jakacki R, Kurczynski E, Needle M, Finlay J, Reaman G, Boyett JM. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;86:747-754. (Pubitemid 27187674)
86. Ater J, Holmes E, Zhou T, Mazewski C, Roberts W, Vezina G, Booth T, Freyer D, Kadota R, Jakacki R, Packer R, Prados M, Pollack I. Abstracts from the thirteenth international symposium on pediatric neuro-oncology: Results of COG protocol A9952-a randomized phase 3 study of two chemotherapy regimens for incompletely resected low-grade glioma in young children. Neuro Oncol. 2008;10:451.
87. Yu DY, Dahl GV, Shames RS, Fisher PG. Weekly dosing of carboplatin increases risk of allergy in children. J Pediatr Hematol Oncol. 2001;23:349-352. (Pubitemid 32845660)
88. Lafay-Cousin L, Sung L, Carret AS, Hukin J, Wilson B, Johnston DL, Zelcer S, SilvaM, Odame I, Mpofu C, Strother D, Bouffet E. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: A Canadian Pediatric Brain Tumor Consortium experience. Cancer. 2008;112:892-899. (Pubitemid 351240583)
89. Massimino M, Spreafico F, Cefalo G, Riccardi R, Tesoro-Tess JD, Gandola L, Riva D, Ruggiero A, Valentini L, Mazza E, Genitori L, Di Rocco C, Navarria P, Casanova M, Ferrari A, Luksch R, Terenziani M, Balestrini MR, Colosimo C, Fossati-Bellani F. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol. 2002; 20:4209-4216. (Pubitemid 35191023)
90. Gururangan S, Fisher MJ, Allen JC, Herndon JE II, Quinn JA, Reardon DA, Vredenburgh JJ, Desjardins A, Phillips PC, Watral MA, Krauser JM, Friedman AH, Friedman HS. Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007;9:161-168. (Pubitemid 46580317)
91. Bouffet E, Jakacki R, Goldman S, Hargrave D, Shroff M, Hukin J, Bartels U, Farley S, Baruchel S. Abstracts from the thirteenth international symposium on pediatric neurooncology: Phase II study of weekly vinblastine in recurrent/ refractory pediatric low-grade gliomas. Neuro Oncol. 2008; 10:450.
92. Packer RJ, Jakacki R, HornM, Rood B, Vezina G,MacDonald T, Fisher MJ, Cohen B. Objective response of multiply recurrent pediatric low-grade gliomas to bevacizumab and irnotecan. Pediatr Blood Cancer. 2009;52:791-795.